GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00105924 | Colorectum | CRC | positive regulation of lamellipodium assembly | 13/2078 | 29/18723 | 4.55e-06 | 1.87e-04 | 13 |
GO:19033625 | Colorectum | CRC | regulation of cellular protein catabolic process | 53/2078 | 255/18723 | 4.58e-06 | 1.87e-04 | 53 |
GO:00161974 | Colorectum | CRC | endosomal transport | 49/2078 | 230/18723 | 5.07e-06 | 2.05e-04 | 49 |
GO:00610143 | Colorectum | CRC | positive regulation of mRNA catabolic process | 25/2078 | 87/18723 | 5.27e-06 | 2.12e-04 | 25 |
GO:00481935 | Colorectum | CRC | Golgi vesicle transport | 59/2078 | 296/18723 | 5.47e-06 | 2.17e-04 | 59 |
GO:00322735 | Colorectum | CRC | positive regulation of protein polymerization | 34/2078 | 138/18723 | 5.47e-06 | 2.17e-04 | 34 |
GO:00486383 | Colorectum | CRC | regulation of developmental growth | 64/2078 | 330/18723 | 5.74e-06 | 2.26e-04 | 64 |
GO:19035803 | Colorectum | CRC | positive regulation of ATP metabolic process | 15/2078 | 38/18723 | 5.82e-06 | 2.28e-04 | 15 |
GO:00105064 | Colorectum | CRC | regulation of autophagy | 62/2078 | 317/18723 | 6.04e-06 | 2.35e-04 | 62 |
GO:00300323 | Colorectum | CRC | lamellipodium assembly | 22/2078 | 72/18723 | 6.40e-06 | 2.47e-04 | 22 |
GO:00434344 | Colorectum | CRC | response to peptide hormone | 76/2078 | 414/18723 | 6.67e-06 | 2.56e-04 | 76 |
GO:00228982 | Colorectum | CRC | regulation of transmembrane transporter activity | 56/2078 | 278/18723 | 6.75e-06 | 2.58e-04 | 56 |
GO:00514955 | Colorectum | CRC | positive regulation of cytoskeleton organization | 48/2078 | 226/18723 | 6.88e-06 | 2.61e-04 | 48 |
GO:00459813 | Colorectum | CRC | positive regulation of nucleotide metabolic process | 16/2078 | 43/18723 | 7.05e-06 | 2.64e-04 | 16 |
GO:19005443 | Colorectum | CRC | positive regulation of purine nucleotide metabolic process | 16/2078 | 43/18723 | 7.05e-06 | 2.64e-04 | 16 |
GO:00190805 | Colorectum | CRC | viral gene expression | 26/2078 | 94/18723 | 7.43e-06 | 2.72e-04 | 26 |
GO:00313464 | Colorectum | CRC | positive regulation of cell projection organization | 67/2078 | 353/18723 | 7.45e-06 | 2.72e-04 | 67 |
GO:00420583 | Colorectum | CRC | regulation of epidermal growth factor receptor signaling pathway | 22/2078 | 73/18723 | 8.21e-06 | 2.96e-04 | 22 |
GO:00310984 | Colorectum | CRC | stress-activated protein kinase signaling cascade | 51/2078 | 247/18723 | 8.35e-06 | 3.00e-04 | 51 |
GO:00324122 | Colorectum | CRC | regulation of ion transmembrane transporter activity | 54/2078 | 267/18723 | 8.67e-06 | 3.09e-04 | 54 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AR | SNV | Missense_Mutation | | c.2595N>A | p.Asp865Glu | p.D865E | P10275 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
AR | SNV | Missense_Mutation | | c.1912N>A | p.Leu638Met | p.L638M | P10275 | protein_coding | tolerated(0.07) | benign(0.316) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
AR | SNV | Missense_Mutation | novel | c.1082N>A | p.Ser361Asn | p.S361N | P10275 | protein_coding | tolerated_low_confidence(0.27) | benign(0.015) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1681N>A | p.Leu561Met | p.L561M | P10275 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1703C>T | p.Ser568Phe | p.S568F | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
AR | SNV | Missense_Mutation | novel | c.2642N>A | p.Leu881Gln | p.L881Q | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A66K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | novel | c.585N>T | p.Gln195His | p.Q195H | P10275 | protein_coding | tolerated_low_confidence(0.13) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.2718N>T | p.Lys906Asn | p.K906N | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.967N>A | p.Glu323Lys | p.E323K | P10275 | protein_coding | tolerated_low_confidence(0.11) | benign(0.265) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
AR | SNV | Missense_Mutation | | c.2462G>T | p.Gly821Val | p.G821V | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | FLUOCINOLONE ACETONIDE | FLUOCINOLONE ACETONIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 4-CHLOROMERCURIBENZOIC ACID | 4-CHLOROMERCURIBENZOIC ACID | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | agonist | CHEMBL2107067 | TESTOSTERONE UNDECANOATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | DIDECYLDIMETHYLAMMONIUM CHLORIDE | DIDECYLDIMETHYLAMMONIUM CHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | QUININE SULFATE | QUININE SULFATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | NILUTAMIDE | NILUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | RALOXIFENE HYDROCHLORIDE | RALOXIFENE HYDROCHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | ARN-509 | APALUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | CRUFOMATE | CRUFOMATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 2-AMINOFLURENE | CHEMBL84472 | |